Premium
In vivo imaging of tumor response to therapy using a dual‐modality imaging strategy
Author(s) -
Medarova Zdravka,
Pham Wellington,
Kim Young,
Dai Guangping,
Moore Anna
Publication year - 2006
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.21672
Subject(s) - modality (human–computer interaction) , in vivo , cancer imaging , medicine , preclinical imaging , treatment modality , medical physics , radiology , cancer , computer science , biology , artificial intelligence , microbiology and biotechnology
Abstract In vivo assessment of the outcome of cancer therapy is hampered by the paucity of imaging probes that target tumors specifically and noninvasively. The importance of such probes increases with the continuous development of chemotherapeutics and the necessity to evaluate their effectiveness in a clinical setting. We have recently reported on a dual‐modality imaging probe specifically targeting the underglycosylated mucin‐1 tumor‐specific antigen (uMUC‐1), which is one of the early hallmarks of tumorigenesis in a wide variety of tumors. This probe consists of crosslinked superparamagnetic iron oxide nanoparticles (CLIO) for MR imaging, modified with Cy5.5 dye (for near infrared optical fluorescence imaging (NIRF)), and has peptides (EPPT), specifically recognizing uMUC‐1, attached to the nanoparticle's dextran coat. In the present study, we demonstrated that this probe could not only detect orthotopically implanted preclinical models of adenocarcinomas but could also track tumor response to chemotherapy in vivo in real time. Considering the high cost associated with the development and testing of new cancer therapeutics and the need for accurate, noninvasive assessment of their effectiveness, we believe that the developed probe represents a valuable research tool relevant to clinical discovery. © 2005 Wiley‐Liss, Inc.